The road from AKI to CKD: The role of endothelin

Kidney International

Volumn 84, Issue 4, 2013, Pages 637-638

  Dhaun, Neeraj ^a   Webb, David J ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST;

ACUTE KIDNEY FAILURE; CELL LOSS; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE PREDISPOSITION; ET 1 GENE; GENE; HISTONE MODIFICATION; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY BLOOD FLOW; KIDNEY HYPERTROPHY; KIDNEY INJURY; MORTALITY; NEPHRON; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; RENOVASCULAR HYPERTENSION; REVIEW; UPREGULATION; VASOCONSTRICTION;

ANIMALS; DISEASE PROGRESSION; ENDOTHELIN-1; KIDNEY FAILURE, CHRONIC; MALE; RENAL INSUFFICIENCY, CHRONIC; REPERFUSION INJURY;

EID: 84885194098     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.158     Document Type: Note

References (14)

1. Zager RA, Johnson ACM, Andress D et al. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury. Kidney Int 2013; 84: 703-712.
2. Ali T, Khan I, Simpson W et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 2007; 18: 1292-1298.
3. Uchino S, Kellum JA, Bellomo R et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-818.
4. Hsu CY. Where is the epidemic in kidney disease? J Am Soc Nephrol 2010; 21: 1607-1611.
5. Chawla LS, Amdur RL, Amodeo S et al. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 2011; 79: 1361-1369.
6. Ishani A, Xue JL, Himmelfarb J et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20: 223-228.
7. Wald R, Quinn RR, Luo J et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 2009; 302: 1179-1185.
8. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006; 17: 943-955.
9. Hostetter TH. Progression of renal disease and renal hypertrophy. Annu Rev Physiol 1995; 57: 263-278.
10. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006; 17: 1503-1520.
11. Arfian N, Emoto N, Vignon-Zellweger N et al. ET-1 deletion from endothelial cells protects the kidney during the extension phase of ischemia/reperfusion injury. Biochem Biophys Res Commun 2012; 425: 443-449.
12. Fenhammar J, Andersson A, Forestier J et al. Endothelin receptor A antagonism attenuates renal medullary blood flow impairment in endotoxemic pigs. PLoS One 2011; 6: e21534.
13. Gulmen S, Kiris I, Narin C et al. Tezosentan reduces the renal injury induced by abdominal aortic ischemia-reperfusion in rats. J Surg Res 2009; 157: e7-e13.
14. RADAR: Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with Atrasentan. A Phase 2b, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Efficacy. Clinical Trials. http://www.clinicaltrials.gov/ct2/show/NCT01356849?term=atrasentan& rank=2. Accessed 24 May 2013.